TASCHUNDA CARTER: Open Payments
NPI 1144949397 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$451 in 17 payments from 7 companies in 2025. Trend: 2023 $745 · 2024 $632 · 2025 $451
Food & beverage: $451
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $148 |
| Janssen Pharmaceuticals, Inc | 5 | $108 |
| Neurocrine BioSciences, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Alkermes, Inc. | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
Products named: REXULTI, INVEGA SUSTENNA, INGREZZA, UZEDY, ARISTADA, COBENFY, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE.
Industry payments across LA — which companies pay providers there.
